Sicmon10 mg+10 mg

Sicmon is a fixed-dose combination of a vitamin B6 analogue (pyridoxine) and a sedating antihistamine (doxylamine) used specifically for one indication:

• Nausea and vomiting of pregnancy (NVP): Established, FDA-approved treatment of nausea and vomiting of pregnancy in women who have not responded adequately to conservative management (dietary and lifestyle changes such as eating small frequent meals, avoiding triggers, and rest).

Sicmon is not indicated for morning sickness prevention before symptoms occur, for hyperemesis gravidarum requiring intravenous therapy or hospitalization, or for nausea/vomiting due to other causes. It is not intended for use as a general antihistamine or sleep aid, although the individual components have those actions off-label.

Each delayed-release tablet of Pyridoxine Hydrochloride + Doxylamine Succinate typically contains Pyridoxine Hydrochloride and Doxylamine Succinate in equal strengths, most commonly available in Bangladesh as 10 mg + 10 mg and 20 mg + 20 mg delayed-release tablet formulations.

Sicmon is an oral, delayed-release combination product combining Pyridoxine Hydrochloride (vitamin B6) with Doxylamine Succinate, a sedating first-generation ethanolamine-class antihistamine. This specific combination is a well-established, guideline-recognized first-line pharmacologic option for nausea and vomiting of pregnancy when non-drug measures alone are insufficient.

The delayed-release formulation is designed to release the medication several hours after dosing, allowing bedtime administration to provide symptom control through the following morning, when NVP symptoms are often most severe.

Antiemetic combination (Antihistamine + Vitamin B6 analogue); Sicmon belongs to the pregnancy-specific antiemetic class.

Pyridoxine Hydrochloride + Doxylamine Succinate combines two components with complementary, though not fully separately defined, mechanisms in nausea and vomiting of pregnancy:

• Doxylamine succinate is a first-generation H1-receptor antihistamine of the ethanolamine class with pronounced central nervous system depressant (sedative) and anticholinergic properties. Its antiemetic action in NVP is believed to relate to these central sedative and anticholinergic effects, though the precise mechanism in pregnancy-related nausea is not completely established.
• Pyridoxine hydrochloride is a synthetic form of vitamin B6, an essential cofactor in amino acid, neurotransmitter, and carbohydrate metabolism. Its mechanism of antiemetic action in NVP is not fully understood, though it has independently shown benefit for NVP in clinical trials.

The combination has been shown in randomized controlled trials to be more effective than either component alone for reducing NVP symptom severity.

• Take Sicmon tablets whole; do not crush, split, chew, or dissolve them, as this destroys the delayed-release mechanism.
• Take on an empty stomach with a glass of water for reliable absorption.
• The bedtime dose should be taken at bedtime to allow the medication to act through the early morning hours.
• Do not exceed the maximum recommended daily dose unless directed by a physician.

Clinically significant interactions with Sicmon include:

• Monoamine oxidase inhibitors (MAOIs): Contraindicated in combination. MAOIs prolong and intensify the anticholinergic and CNS-depressant (sedative) effects of the doxylamine component.
• Alcohol and other CNS depressants (e.g. opioids, benzodiazepines, sedative-hypnotics): Additive sedation and CNS depression; concurrent use should be avoided or undertaken with caution.
• Other anticholinergic drugs (e.g. tricyclic antidepressants, certain antipsychotics): Additive anticholinergic effects such as dry mouth, urinary retention, and constipation.

The most common adverse effect of Sicmon is somnolence (drowsiness), reported frequently and reflecting the sedating antihistamine component; patients should be cautioned about driving or operating machinery until they know how it affects them. Other reported effects include:

• Dry mouth
• Dizziness
• Headache
• Irritability
• Less commonly, other anticholinergic effects such as urinary retention or blurred vision

Pregnancy: Sicmon is specifically indicated for use during pregnancy to treat nausea and vomiting of pregnancy and is a well-established, guideline-recognized first-line pharmacologic option when conservative measures are insufficient. Extensive human safety data support its use for this labeled indication when taken exactly as directed by a physician; it should still only be used as prescribed and for as long as clinically needed.

Lactation: Doxylamine, a sedating antihistamine, passes into breast milk and may cause drowsiness or other effects in a breastfeeding infant. Sicmon should be used during breastfeeding only with caution and under physician guidance, weighing benefit against potential infant sedation.

• Sedation: Sicmon commonly causes drowsiness; patients should avoid driving, operating heavy machinery, or other activities requiring mental alertness until they know how the medication affects them, and should avoid alcohol and other CNS depressants (see Interactions).
• Anticholinergic caution: Use with caution in patients with asthma or other chronic respiratory impairment, narrow-angle glaucoma, or urinary retention (e.g. due to bladder-neck obstruction or benign prostatic hyperplasia), as the doxylamine component's anticholinergic effects may worsen these conditions.
• Do not exceed the recommended maximum dose. Take exactly as directed by a physician; do not adjust the dose without medical advice.

Overdose of Sicmon is primarily a doxylamine (antihistamine) overdose and can cause anticholinergic toxicity, including restlessness, hallucinations, dilated pupils, dry flushed skin, tremor, and, in severe cases, seizures progressing to profound CNS and respiratory depression, particularly in young children who may show paradoxical excitation rather than sedation.

There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away; management is supportive and should only be carried out by qualified medical personnel. Do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pregnant women: This is the labeled population for Sicmon; use as directed by a physician for nausea and vomiting of pregnancy (see Pregnancy and Lactation).
• Breastfeeding women: Use with caution under physician guidance due to potential infant drowsiness (see Pregnancy and Lactation).
• Pediatric patients: Safety and efficacy have not been established; Sicmon has no pediatric indication.
• Elderly: Not a typical population for this indication, but if exposed, elderly patients may be more sensitive to the anticholinergic and sedative effects of the doxylamine component (e.g. confusion, dizziness, urinary retention); use with added caution.
• Renal/hepatic impairment: Use with caution; formal dose-adjustment data are not well established (see Dosage and Administration).

Sicmon should be used for as long as nausea and vomiting of pregnancy symptoms persist and require treatment, at the lowest effective dose. Many patients continue through the period of highest NVP symptom burden (commonly the first trimester, though symptoms can persist longer) and discontinue once symptoms resolve or delivery occurs, under ongoing physician assessment. Treatment duration should be periodically reassessed by the prescribing physician rather than continued indefinitely without review.

Antihistamine (H1-receptor antagonist, ethanolamine class) combined with a Vitamin B6 analogue; classified as a pregnancy-specific antiemetic. Pyridoxine Hydrochloride + Doxylamine Succinate is the only agent in this exact fixed-dose combination class marketed for this indication.

Pyridoxine Hydrochloride + Doxylamine Succinate acts through the combined central antihistaminic/anticholinergic sedative action of doxylamine and the metabolic cofactor role of pyridoxine (vitamin B6); see Pharmacology for full mechanistic detail. The complementary action of the two components produces greater antiemetic efficacy in nausea and vomiting of pregnancy than either agent used alone.

A (US FDA legacy pregnancy category; based on adequate, well-controlled human studies specifically in pregnant women for this indication)

Sicmon has no approved pediatric indication. Safety and efficacy in pediatric patients have not been established, as this combination is specifically indicated for nausea and vomiting of pregnancy in adult women. It should not be used in children or adolescents outside of this labeled adult obstetric indication.